Axela | GenomeWeb

Axela

The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.

The partners will work together to develop serological assays measuring antibodies to determine patient immunity to diseases for which vaccines exist.

Axela and Hutman Diagnostics last week announced progress in the co-development of a multiplex pathogen detection system.

Axela and Hutman Diagnostics have announced an agreement that will deliver a microarray-based, sample-to-answer pathogen detection platform to market next year.

NEW YORK (GenomeWeb News) – Axela today announced a development deal to integrate Thermal Gradient's rapid PCR technology into Axela's Flow-Thru Chip automated workflow.

NEW YORK (GenomeWeb News) – Multiplex instrument developer Axela today announced the hiring of investment bank AmeriTech Advisors to explore strategic opportunities for the firm.

Axela and OvaGene Oncology this week announced a partnership that will see OvaGene's gene signatures related to ovarian cancer treatment become available on Axela's Ziplex array platform.

NEW YORK (GenomeWeb News) – Mount Sinai Services in Toronto and Brigham and Women's Hospital in Boston are collaborating to test Axela's Risk of Recurrence Assay, the company said today.

NEW YORK (GenomeWeb News) – Isogen Life Science will distribute Axela's multiplex biomarker platforms in Benelux and Spain under an agreement announced by the firms today.

Pages

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.